China · Delayed Price · Currency is CNY Suzhou Zelgen Biopharmaceuticals Company Description
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China.
The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for hemostasis.
It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, and myelofibrosis; recombinant human thyroid-stimulating hormone for injection; and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and other advanced tumors.
In addition, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and other advanced tumors; and ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors.
The company’s products are used in multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. was founded in 2009 and is based in Kunshan, the People's Republic of China.
| Country | China |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,055 |
| CEO | Zelin Sheng |
Contact Details
Address: No. 209, Chenfeng Road Kunshan, 215300 China | |
| Phone | 86 512 5701 8310 |
| Website | zelgen.com |
Stock Details
| Ticker Symbol | 688266 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003RP1 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Zelin Sheng | Chairman of the Board and GM |
| Gang Huang | Chief Financial Officer and Deputy GM |
| Zeqi Sheng | Chief Scientific Officer |
| Huiping Lu | Executive Vice President and Director |
| Jisheng Wu | Director and Deputy GM |
| Binhua Lyu | Deputy GM, Executive Vice President of Chemistry and Director |
| Qingping Gao | Deputy GM and Board Secretary |
| Shice Shao | Accounting Supervisor |